Radiotherapy for invasive thymoma and thymic carcinoma: Clinicopathological review
This study reports clinicopathological features and outcome of thymic tumors. Twenty-seven patients with invasive thymoma and 6 patients with thymic carcinoma who had received radiotherapy either primary or postoperatively were analyzed retrospectively. All 33 patients were irradiated with a mean do...
Gespeichert in:
| Veröffentlicht in: | Strahlentherapie und Onkologie 1999-06, Vol.175 (6), p.271-278 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 278 |
|---|---|
| container_issue | 6 |
| container_start_page | 271 |
| container_title | Strahlentherapie und Onkologie |
| container_volume | 175 |
| creator | MAYER, R BEHAM-SCHMID, C GROELL, R SMOLLE-JUETTNER, F.-M QUEHENBERGER, F STUECKLSCHWEIGER, G. F PRETTENHOFER, U STRANZL, H RENNER, H HACKL, A |
| description | This study reports clinicopathological features and outcome of thymic tumors. Twenty-seven patients with invasive thymoma and 6 patients with thymic carcinoma who had received radiotherapy either primary or postoperatively were analyzed retrospectively.
All 33 patients were irradiated with a mean dose of 50 Gy after complete resection (16 patients), partial resection (9 patients) or biopsy (8 patients). Staging was done according to the Masaoka classification; there were 12 Stage II, 12 Stage III and 9 Stage IV patients.
In patients with invasive thymoma Stage II to IV (median follow-up 54.4 months) Kaplan-Meier estimates of overall survival (OS), disease-specific (DSS) and disease-free survival (DFS) at 5 years were 63.7% (95% confidence interval [CI], 42 to 84%), 88.3% (CI, 75 to 100%) and 77.4% (CI, 58 to 95%), respectively. Among the prognostic factors tested, such as age, myasthenia gravis, completeness of surgery and histologic subclassification, total radiation dose, and Masaoka Stage, the latter was the only significant predictor of improved survival (p = 0.04). Considering local control, radiation dose was a significant prognostic factor (p = 0.0006). In patients with thymic carcinoma (median follow-up 43.4 months) 5-year DSS, and DFS were 22.2% (CI, 0 to 60%) and 16.7% (CI, 0 to 46%), respectively. Thymoma as compared to thymic carcinoma had a statistically significant better DSS (p = 0.007) and DFS (p = 0.0007).
Postoperative radiotherapy with sufficient doses plays an important role as adjuvant treatment in complete or incomplete resected invasive Stage II to III thymoma. In unresectable thymoma Stage III to IV as well as in thymic carcinoma a multimodality approach should be considered to improve survival. |
| doi_str_mv | 10.1007/BF02743578 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69866162</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69866162</sourcerecordid><originalsourceid>FETCH-LOGICAL-c271t-ced8f8ea67c5b4d44f13ce6ee92742379ec86596cf50d9ebdb6f04420f6522bd3</originalsourceid><addsrcrecordid>eNpN0EFLwzAUB_AgipvTix9AehAPQjVJ06TxpsOpMBCGgreSJi8u0jY16Sb79lY30NN7PH784f0ROiX4imAsru9mmAqW5aLYQ2PCMpliKd_20RgTIVNB8mKEjmL8wJhwJtkhGhGcSUp4MUaLhTLO90sIqtsk1ofEtWsV3RqSfrlpfKMS1Zrf3elEq6BdOxxvkmntWqd9p_qlr_2706pOAqwdfB2jA6vqCCe7OUGvs_uX6WM6f354mt7OU00F6VMNprAFKC50XjHDmCWZBg4gh2doJiTogueSa5tjI6EyFbeYMYotzymtTDZBF9vcLvjPFcS-bFzUUNeqBb-KJZcF54TTAV5uoQ4-xgC27IJrVNiUBJc_DZZ_DQ74bJe6qhow_-i2sgGc74CKw9M2qFa7-OcKISiX2TdcbnlP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69866162</pqid></control><display><type>article</type><title>Radiotherapy for invasive thymoma and thymic carcinoma: Clinicopathological review</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>MAYER, R ; BEHAM-SCHMID, C ; GROELL, R ; SMOLLE-JUETTNER, F.-M ; QUEHENBERGER, F ; STUECKLSCHWEIGER, G. F ; PRETTENHOFER, U ; STRANZL, H ; RENNER, H ; HACKL, A</creator><creatorcontrib>MAYER, R ; BEHAM-SCHMID, C ; GROELL, R ; SMOLLE-JUETTNER, F.-M ; QUEHENBERGER, F ; STUECKLSCHWEIGER, G. F ; PRETTENHOFER, U ; STRANZL, H ; RENNER, H ; HACKL, A</creatorcontrib><description>This study reports clinicopathological features and outcome of thymic tumors. Twenty-seven patients with invasive thymoma and 6 patients with thymic carcinoma who had received radiotherapy either primary or postoperatively were analyzed retrospectively.
All 33 patients were irradiated with a mean dose of 50 Gy after complete resection (16 patients), partial resection (9 patients) or biopsy (8 patients). Staging was done according to the Masaoka classification; there were 12 Stage II, 12 Stage III and 9 Stage IV patients.
In patients with invasive thymoma Stage II to IV (median follow-up 54.4 months) Kaplan-Meier estimates of overall survival (OS), disease-specific (DSS) and disease-free survival (DFS) at 5 years were 63.7% (95% confidence interval [CI], 42 to 84%), 88.3% (CI, 75 to 100%) and 77.4% (CI, 58 to 95%), respectively. Among the prognostic factors tested, such as age, myasthenia gravis, completeness of surgery and histologic subclassification, total radiation dose, and Masaoka Stage, the latter was the only significant predictor of improved survival (p = 0.04). Considering local control, radiation dose was a significant prognostic factor (p = 0.0006). In patients with thymic carcinoma (median follow-up 43.4 months) 5-year DSS, and DFS were 22.2% (CI, 0 to 60%) and 16.7% (CI, 0 to 46%), respectively. Thymoma as compared to thymic carcinoma had a statistically significant better DSS (p = 0.007) and DFS (p = 0.0007).
Postoperative radiotherapy with sufficient doses plays an important role as adjuvant treatment in complete or incomplete resected invasive Stage II to III thymoma. In unresectable thymoma Stage III to IV as well as in thymic carcinoma a multimodality approach should be considered to improve survival.</description><identifier>ISSN: 0179-7158</identifier><identifier>EISSN: 1439-099X</identifier><identifier>DOI: 10.1007/BF02743578</identifier><identifier>PMID: 10392168</identifier><identifier>CODEN: STONE4</identifier><language>eng</language><publisher>München: Springer</publisher><subject>Actuarial Analysis ; Adult ; Aged ; Biological and medical sciences ; Biopsy ; Combined Modality Therapy ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Male ; Medical sciences ; Middle Aged ; Miscellaneous ; Neoplasm Invasiveness ; Neoplasm Staging ; Radiotherapy Dosage ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Retrospective Studies ; Survival Analysis ; Thymoma - mortality ; Thymoma - pathology ; Thymoma - radiotherapy ; Thymoma - surgery ; Thymus Neoplasms - mortality ; Thymus Neoplasms - pathology ; Thymus Neoplasms - radiotherapy ; Thymus Neoplasms - surgery ; Time Factors</subject><ispartof>Strahlentherapie und Onkologie, 1999-06, Vol.175 (6), p.271-278</ispartof><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c271t-ced8f8ea67c5b4d44f13ce6ee92742379ec86596cf50d9ebdb6f04420f6522bd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1877269$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10392168$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MAYER, R</creatorcontrib><creatorcontrib>BEHAM-SCHMID, C</creatorcontrib><creatorcontrib>GROELL, R</creatorcontrib><creatorcontrib>SMOLLE-JUETTNER, F.-M</creatorcontrib><creatorcontrib>QUEHENBERGER, F</creatorcontrib><creatorcontrib>STUECKLSCHWEIGER, G. F</creatorcontrib><creatorcontrib>PRETTENHOFER, U</creatorcontrib><creatorcontrib>STRANZL, H</creatorcontrib><creatorcontrib>RENNER, H</creatorcontrib><creatorcontrib>HACKL, A</creatorcontrib><title>Radiotherapy for invasive thymoma and thymic carcinoma: Clinicopathological review</title><title>Strahlentherapie und Onkologie</title><addtitle>Strahlenther Onkol</addtitle><description>This study reports clinicopathological features and outcome of thymic tumors. Twenty-seven patients with invasive thymoma and 6 patients with thymic carcinoma who had received radiotherapy either primary or postoperatively were analyzed retrospectively.
All 33 patients were irradiated with a mean dose of 50 Gy after complete resection (16 patients), partial resection (9 patients) or biopsy (8 patients). Staging was done according to the Masaoka classification; there were 12 Stage II, 12 Stage III and 9 Stage IV patients.
In patients with invasive thymoma Stage II to IV (median follow-up 54.4 months) Kaplan-Meier estimates of overall survival (OS), disease-specific (DSS) and disease-free survival (DFS) at 5 years were 63.7% (95% confidence interval [CI], 42 to 84%), 88.3% (CI, 75 to 100%) and 77.4% (CI, 58 to 95%), respectively. Among the prognostic factors tested, such as age, myasthenia gravis, completeness of surgery and histologic subclassification, total radiation dose, and Masaoka Stage, the latter was the only significant predictor of improved survival (p = 0.04). Considering local control, radiation dose was a significant prognostic factor (p = 0.0006). In patients with thymic carcinoma (median follow-up 43.4 months) 5-year DSS, and DFS were 22.2% (CI, 0 to 60%) and 16.7% (CI, 0 to 46%), respectively. Thymoma as compared to thymic carcinoma had a statistically significant better DSS (p = 0.007) and DFS (p = 0.0007).
Postoperative radiotherapy with sufficient doses plays an important role as adjuvant treatment in complete or incomplete resected invasive Stage II to III thymoma. In unresectable thymoma Stage III to IV as well as in thymic carcinoma a multimodality approach should be considered to improve survival.</description><subject>Actuarial Analysis</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>Combined Modality Therapy</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Staging</subject><subject>Radiotherapy Dosage</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Thymoma - mortality</subject><subject>Thymoma - pathology</subject><subject>Thymoma - radiotherapy</subject><subject>Thymoma - surgery</subject><subject>Thymus Neoplasms - mortality</subject><subject>Thymus Neoplasms - pathology</subject><subject>Thymus Neoplasms - radiotherapy</subject><subject>Thymus Neoplasms - surgery</subject><subject>Time Factors</subject><issn>0179-7158</issn><issn>1439-099X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpN0EFLwzAUB_AgipvTix9AehAPQjVJ06TxpsOpMBCGgreSJi8u0jY16Sb79lY30NN7PH784f0ROiX4imAsru9mmAqW5aLYQ2PCMpliKd_20RgTIVNB8mKEjmL8wJhwJtkhGhGcSUp4MUaLhTLO90sIqtsk1ofEtWsV3RqSfrlpfKMS1Zrf3elEq6BdOxxvkmntWqd9p_qlr_2706pOAqwdfB2jA6vqCCe7OUGvs_uX6WM6f354mt7OU00F6VMNprAFKC50XjHDmCWZBg4gh2doJiTogueSa5tjI6EyFbeYMYotzymtTDZBF9vcLvjPFcS-bFzUUNeqBb-KJZcF54TTAV5uoQ4-xgC27IJrVNiUBJc_DZZ_DQ74bJe6qhow_-i2sgGc74CKw9M2qFa7-OcKISiX2TdcbnlP</recordid><startdate>19990601</startdate><enddate>19990601</enddate><creator>MAYER, R</creator><creator>BEHAM-SCHMID, C</creator><creator>GROELL, R</creator><creator>SMOLLE-JUETTNER, F.-M</creator><creator>QUEHENBERGER, F</creator><creator>STUECKLSCHWEIGER, G. F</creator><creator>PRETTENHOFER, U</creator><creator>STRANZL, H</creator><creator>RENNER, H</creator><creator>HACKL, A</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19990601</creationdate><title>Radiotherapy for invasive thymoma and thymic carcinoma: Clinicopathological review</title><author>MAYER, R ; BEHAM-SCHMID, C ; GROELL, R ; SMOLLE-JUETTNER, F.-M ; QUEHENBERGER, F ; STUECKLSCHWEIGER, G. F ; PRETTENHOFER, U ; STRANZL, H ; RENNER, H ; HACKL, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c271t-ced8f8ea67c5b4d44f13ce6ee92742379ec86596cf50d9ebdb6f04420f6522bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Actuarial Analysis</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>Combined Modality Therapy</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Staging</topic><topic>Radiotherapy Dosage</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Thymoma - mortality</topic><topic>Thymoma - pathology</topic><topic>Thymoma - radiotherapy</topic><topic>Thymoma - surgery</topic><topic>Thymus Neoplasms - mortality</topic><topic>Thymus Neoplasms - pathology</topic><topic>Thymus Neoplasms - radiotherapy</topic><topic>Thymus Neoplasms - surgery</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MAYER, R</creatorcontrib><creatorcontrib>BEHAM-SCHMID, C</creatorcontrib><creatorcontrib>GROELL, R</creatorcontrib><creatorcontrib>SMOLLE-JUETTNER, F.-M</creatorcontrib><creatorcontrib>QUEHENBERGER, F</creatorcontrib><creatorcontrib>STUECKLSCHWEIGER, G. F</creatorcontrib><creatorcontrib>PRETTENHOFER, U</creatorcontrib><creatorcontrib>STRANZL, H</creatorcontrib><creatorcontrib>RENNER, H</creatorcontrib><creatorcontrib>HACKL, A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Strahlentherapie und Onkologie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MAYER, R</au><au>BEHAM-SCHMID, C</au><au>GROELL, R</au><au>SMOLLE-JUETTNER, F.-M</au><au>QUEHENBERGER, F</au><au>STUECKLSCHWEIGER, G. F</au><au>PRETTENHOFER, U</au><au>STRANZL, H</au><au>RENNER, H</au><au>HACKL, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiotherapy for invasive thymoma and thymic carcinoma: Clinicopathological review</atitle><jtitle>Strahlentherapie und Onkologie</jtitle><addtitle>Strahlenther Onkol</addtitle><date>1999-06-01</date><risdate>1999</risdate><volume>175</volume><issue>6</issue><spage>271</spage><epage>278</epage><pages>271-278</pages><issn>0179-7158</issn><eissn>1439-099X</eissn><coden>STONE4</coden><abstract>This study reports clinicopathological features and outcome of thymic tumors. Twenty-seven patients with invasive thymoma and 6 patients with thymic carcinoma who had received radiotherapy either primary or postoperatively were analyzed retrospectively.
All 33 patients were irradiated with a mean dose of 50 Gy after complete resection (16 patients), partial resection (9 patients) or biopsy (8 patients). Staging was done according to the Masaoka classification; there were 12 Stage II, 12 Stage III and 9 Stage IV patients.
In patients with invasive thymoma Stage II to IV (median follow-up 54.4 months) Kaplan-Meier estimates of overall survival (OS), disease-specific (DSS) and disease-free survival (DFS) at 5 years were 63.7% (95% confidence interval [CI], 42 to 84%), 88.3% (CI, 75 to 100%) and 77.4% (CI, 58 to 95%), respectively. Among the prognostic factors tested, such as age, myasthenia gravis, completeness of surgery and histologic subclassification, total radiation dose, and Masaoka Stage, the latter was the only significant predictor of improved survival (p = 0.04). Considering local control, radiation dose was a significant prognostic factor (p = 0.0006). In patients with thymic carcinoma (median follow-up 43.4 months) 5-year DSS, and DFS were 22.2% (CI, 0 to 60%) and 16.7% (CI, 0 to 46%), respectively. Thymoma as compared to thymic carcinoma had a statistically significant better DSS (p = 0.007) and DFS (p = 0.0007).
Postoperative radiotherapy with sufficient doses plays an important role as adjuvant treatment in complete or incomplete resected invasive Stage II to III thymoma. In unresectable thymoma Stage III to IV as well as in thymic carcinoma a multimodality approach should be considered to improve survival.</abstract><cop>München</cop><pub>Springer</pub><pmid>10392168</pmid><doi>10.1007/BF02743578</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0179-7158 |
| ispartof | Strahlentherapie und Onkologie, 1999-06, Vol.175 (6), p.271-278 |
| issn | 0179-7158 1439-099X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69866162 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Actuarial Analysis Adult Aged Biological and medical sciences Biopsy Combined Modality Therapy Disease-Free Survival Female Follow-Up Studies Humans Male Medical sciences Middle Aged Miscellaneous Neoplasm Invasiveness Neoplasm Staging Radiotherapy Dosage Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Retrospective Studies Survival Analysis Thymoma - mortality Thymoma - pathology Thymoma - radiotherapy Thymoma - surgery Thymus Neoplasms - mortality Thymus Neoplasms - pathology Thymus Neoplasms - radiotherapy Thymus Neoplasms - surgery Time Factors |
| title | Radiotherapy for invasive thymoma and thymic carcinoma: Clinicopathological review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T19%3A08%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiotherapy%20for%20invasive%20thymoma%20and%20thymic%20carcinoma:%20Clinicopathological%20review&rft.jtitle=Strahlentherapie%20und%20Onkologie&rft.au=MAYER,%20R&rft.date=1999-06-01&rft.volume=175&rft.issue=6&rft.spage=271&rft.epage=278&rft.pages=271-278&rft.issn=0179-7158&rft.eissn=1439-099X&rft.coden=STONE4&rft_id=info:doi/10.1007/BF02743578&rft_dat=%3Cproquest_cross%3E69866162%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69866162&rft_id=info:pmid/10392168&rfr_iscdi=true |